Lilly Asia Ventures — Full Portfolio
83 tracked investments · listed companies and verified rows first
Clinical-stage biopharmaceutical company focused on identifying, developing and commercializing differentiated medicines for cancer patients.
BiotechMedical DevicesNewtown Square, US
Brent Rice(Chief Commercial Officer)Jason Zhang(Director)Cong Xu(Director)Zhengbin (Bing) Yao(Executive Officer, Director)Stuart Lutzker(Director)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
BiotechSomerset, US
Fangliang Zhang, Ph.D.(Director)Yuan Xu, Ph.D.(Executive Officer, Director)Ying Huang, Ph.D.(Executive Officer)Ye Wang, M.S.(Director)
PartnerHongbo Lu· solo GP
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Timothy Mayer(Executive Officer)Michael Richman(Executive Officer, Director)Elaine V. Jones(Director)Udayan Guha(Executive Officer)Anne Borgman(Director)Steven P. Cobourn(Executive Officer)
PartnerHongbo Lu· solo GP
San Diego, US
Board seatHongbo Lu· per SEC Form D · $5M raise · filed Aug 2020
Glaukos develops surgical and pharmaceutical therapies for ophthalmic diseases including glaucoma, corneal health, and retinal disease.
BiotechHealthtechMedical DevicesWaltham, US
Jason Hong(Director)David F. Muller(Executive Officer, Director)Robert Palmisano(Director)Philip J. Ferneau(Director)M. Carl Johnson, III(Director)David Berry(Director)
Board seatHongbo Lu· per SEC Form D
BiotechSan Diego, US
JINGRONG JEAN CUI(Executive Officer, Director)YISHAN LI(Executive Officer, Director)Jingrong Jean Cui(Executive Officer, Director)Li Peter Yishan(Executive Officer, Director)
BoardGEORGE LEE(Director)CARL GORDON(Director)
Board seatHongbo Lu· per SEC Form D · $100M raise · filed Jan 2024
San Francisco, US
BoardChristy Shaffer(Director)Chau Khuong(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)
Board seatHongbo Lu· per SEC Form D
Rgenta Therapeutics develops small molecule RNA modulation therapies through a discovery platform, aiming to create treatment options for patients with unmet medical needs across multiple therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Judith Li(Director)Debasish Roychowdhury(Director)Travis Wager(Co-founder, President and CSO)Sun Linghao(Director)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)
Board seatHongbo Lu· per SEC Form D · $38M raise · filed Mar 2021
Allist (艾力斯医药) is a biopharmaceutical company that develops innovative drugs, with a product pipeline focused on treatments for non-small cell lung cancer (NSCLC) such as its EGFR-targeted therapy marketed as Furmonertinib (艾弗沙®).
BiotechHealthtech
PartnerHongbo Lu· solo GP
BiotechSan Diego, US
RONALD MOSS(Executive Officer)ALLEN CHAO(Director)MICHAEL CHANG(Director)MARK ATTEBURY(Executive Officer)MIKAEL HAVLUCIYAN(Executive Officer)NANCY CHANG(Director)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
Inhibrx Biosciences, Inc. is a biotechnology company that was spun off as a subsidiary of Inhibrx, Inc. through a pro rata distribution of shares to shareholders.
BiotechLa Jolla, US
Mark Lappe(Executive Officer, Director)Doug Forsyth(Director)Brendan Eckelman(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)
BoardJudith Li(Director)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
GEORGE GOLUMBESKI(Director)RICHARD A. MOSCICKI, PH.D.(Director)ALAN L. CRANE(Director)JAMES GILBERT(Director)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
BiotechSan Diego, US
Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)Ronald Evans(Director)
BoardKristina Burow(Director)Richard Heyman(Director)Amir Nashat(Director)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
NiKang Therapeutics is a clinical-stage biotech company developing small molecule drugs for cancer treatment, focusing on HIF2α, CDK2, and KRAS targets using structure-based drug design.
Biotech
PartnerHongbo Lu· solo GP
BiotechCampbell, US
Amr Salahieh(Executive Officer, Director)Casey Gordon(Director)Mariam Maghribi(Executive Officer)
PartnerHongbo Lu· solo GP
BiotechBrisbane, US
Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
Readcoor develops in situ spatial profiling technology using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections.
BiotechDeep TechHardwareHealthtechCambridge, US
Thomas Grogan(Director)Victor Tong(Director)Richard Terry(Executive Officer, Director)Evan Daugharthy(Cofounder)
BoardYuh-Geng Tsay(Director)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
Singlera Genomics develops DNA methylation-based molecular diagnostics for cancer, covering early detection, diagnosis, and recurrence monitoring across multiple cancer types including colorectal, liver, gastric, esophageal, and pancreatic cancers.
BiotechHealthtechMedical DevicesShanghai, CN
PartnerHongbo Lu· solo GP
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
PartnerHongbo Lu· solo GP
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Fan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)Jeffrey Bluestone(Executive Officer, Director, Promoter)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
BiotechFoster City, US
Weidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)David Fellows(Director)Jeffrey Kindler(Director)Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)
PartnerHongbo Lu· solo GP
BiotechPhiladelphia, US
Kevin Mahoney(Director)Anne Chew(Director and President)
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
PartnerHongbo Lu· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.